In the United States, a black box warning, or black label warning, is a type of warning that appears on the package insert for prescription drugs that may cause serious adverse side effects.

The black box warning is the most severe warning United States Food and Drug Administration can issue. Named for the black borer that commonly surrounds its text, a black box warning means that medical studies indicate that the accompanying drug carries serious or life-threatening risks. The FDA can require a pharmaceutical company to carry the black box warning on the labeling of a drug.

The most black box warning issued by the FDA pertains to gadolinium-based MRI contrast agents. Agents containing gadolinium have been liked to the development of nephrogenic systemic fibrosis (NSF) a potentially fatal skin disorder. The FDA issued a black box warning on all gadolinium-based contrast agents on September 9, 2010.

If you have developed NSF because of gadolinium-based MRI contrast agents, you may be eligible for compensation. Please contact a gadolinium attorney of Williams Kherkher by calling 800-761-3187.

Ireland-based health care product manufacturer Covidien plc has backed the United States Food and Drug Administration's labeling changes for Gadolinium-based MRI contrasting agents for patients with kidney disease.

According to an FDA mandate released on September 9, gadolinium-based contrast agents must carry warnings due to the risk of nephrogenic systemic fibrosis if they are used in patients with kidney disease. NSF is a rare and potentially fatal disorder characterized by the hardening of the skin, eyes, and internal organs.

The correlation between NSF with gadolinium-based contrast agents can be traced back to 2006 when the FDA reported cases of NSF in renal failure patients. Since that time, regulators have been monitoring the effects of all such contrasting agents for their potential to cause this serious disease.

If you have developed NSF of NFD because of gadolinium-based agents, you may be eligible for compensation. Contact a gadolinium lawyer of Williams Kherkher by calling 800-761-3187.

The U.S. Food and Drug Administration said Thursday that certain types of drugs used in MRI scans shouldn't be used in patients with kidney disease because of the risk of developing a rare and potentially fatal skin condition.

The FDA said that MRI contrast agents that are gadolinium-based will carry new warnings on their labels about the risk of nephrogenic systemic fibrosis if the drug is administered to patients with kidney disease. The drugs are also used in a procedure known as magnetic resonance angiography, or MRA.

The agency also named three specific drugs that should be avoided in patients with kidney disease: Covidien PLC's Optimark, Bayer AG's Magnevist and General Electric Co.'s Omniscan. There are seven gadolinium based contrast agents on the market.

If you have developed NSF because of gadolinium-based agents, you may be eligible for compensation. Contact a gadolinium attorney of Williams Kherkher by calling 800-761-3187.

Nephrogenic fibrosing dermopathy is a disease seemingly occurring exclusively in patients with kidney disease which has been linked to gadolinium-based MRI contrast agents.
 
Nephrogenic fibrosing dermopathy may resemble skin diseases like scleroderma and scleromyxedema with thickening pigmentation developing on large areas of skin. The disease can also affect internal organs and cause shortening of muscles and tendons as well as scar tissue.
 
Skin biopsies are used to diagnose nephrogenic fibrosing dermopathy. Diagnosing the disease during its early stage may help slow the progression of the illness.
 
If you have developed NSF of NFD because of gadolinium-based agents, you may be eligible for compensation. Contact a gadolinium lawyer of Williams Kherkher by calling 800-761-3187.